Comparing two biologic drugs for chest pain in axial spondyloarthritis
Treatments studied
Part of Bones, joints & muscles, Pain clinical trials.
This trial tests whether bimekizumab is better than adalimumab at reducing chest wall pain in people with active axial spondyloarthritis who haven't responded to NSAIDs. It aims to find a more effective treatment option for this specific symptom.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed by a rheumatologist with axial spondyloarthritis (with or without psoriasis) according to the ASAS criteria.
- Your disease has been active for more than 3 months.
- You have not previously taken biologic or targeted synthetic DMARDs (like TNF inhibitors or JAK inhibitors).
- You have had an inadequate response or intolerance to at least two NSAIDs (taken for at least 2 weeks each or for at least 3 months if intolerant).
- You have active disease (ASDAS-CRP score ≥ 2.1) and spontaneous chest wall pain of at least 4 out of 10 on a pain scale, with tenderness at one or more of the four chondro-sternal joints.
- You are willing to use effective contraception (if applicable) and have negative pregnancy tests.
- You have no contraindications to the study drugs (e.g., active infections, heart failure, or allergies).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two medicine options (azathioprine vs methotrexate) when added to adalimumab to treat active Crohn’s disease. It may help determine which add-on works better for people whose Crohn’s is still active despite standard treatments or who can’t take them.
This study looks at how well different newer medications work for people with axial spondyloarthritis or psoriatic arthritis. It focuses on those just starting treatment with bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
This study looks at whether giving bimekizumab in different ways is safe and how it moves through the body over time. It is for adults with active psoriatic arthritis or axial spondyloarthritis who may benefit from bimekizumab treatment.
This trial compares two medicines for people with psoriatic arthritis who still have joint, skin, or nail symptoms after methotrexate. One medicine is apremilast (a pill), and the other is adalimumab (an injection). The study aims to see which works better.
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
This trial tests whether combining two biologic medications (adalimumab and secukinumab) can better relieve symptoms of ankylosing spondylitis, a type of arthritis that affects the spine. It may help if you have not responded well to standard nonsteroidal anti-inflammatory drugs (NSAIDs) and you have active disease.
Hear when a new Axial or Predominantly Axial SpondyloArthritis With or Without Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.